← Leaderboards
James C Mulloy
Sloan-Kettering Institute For Cancer Res
$7,243,007
Attributed
$10,850,050
Total exposure
10
Grants
6
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $1.1M · FY2005–24$2M$1.5M$1M$500K$0
'05
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
Funding mix
By agency
NIH$10,850,050 · 10
By mechanism
R01$8,956,980 · 5
K01$711,990 · 1
R21$656,670 · 2
R43$524,410 · 2
Top collaborators
- Yi Zheng11 shared
- Michael J Thirman5 shared
- Hartmut Geiger1 shared
Others in their field
Top investigators on “Leukemia”
- Richard K. Wilson · Washington University$209,620,938
- David Heimbrook · Leidos Biomedical Research, Inc.$168,419,678
- Douglas S. Hawkins · Children'S Hosp Of Philadelphia$157,967,203
- Peter C Adamson · National Childhood Cancer Foundation$143,910,899
- Ralph Parchment · Leidos Biomedical Research, Inc.$141,315,269
- Richard L Schilsky · University Of Chicago$129,102,207
Research focus
LeukemiaCellsSignal TransductionStem CellsIn VitroCd34 GeneSignal PathwayHematopoietic Stem CellsMolecularOncogenesSamplingGene ExpressionChimeric ProteinsSelf-RenewalPathway InteractionsGeneticMaintenanceIn VivoAffectBiological ModelsTransplantationLeukemogenesisMediatingMll-Af9
Grant awards (34)
Pharmacological rejuvenation of human hematopoietic stem cells$299,781
R43 · FY2024 · HL · contact PI
Instructive role of MLL fusion proteins in lineage determination and leukemogenesis$594,545
R01 · FY2021 · CA
Leukemia stem cell polarity and differentiation therapy$442,805
R01 · FY2021 · CA · contact PI
Instructive role of MLL fusion proteins in lineage determination and leukemogenesis$594,545
R01 · FY2020 · CA
Leukemia stem cell polarity and differentiation therapy$442,805
R01 · FY2020 · CA · contact PI
Instructive role of MLL fusion proteins in lineage determination and leukemogenesis$576,709
R01 · FY2019 · CA
Leukemia stem cell polarity and differentiation therapy$429,520
R01 · FY2019 · CA · contact PI
Instructive role of MLL fusion proteins in lineage determination and leukemogenesis$594,545
R01 · FY2018 · CA
Leukemia stem cell polarity and differentiation therapy$442,805
R01 · FY2018 · CA · contact PI
Instructive role of MLL fusion proteins in lineage determination and leukemogenesis$609,178
R01 · FY2017 · CA
Leukemia stem cell polarity and differentiation therapy$442,805
R01 · FY2017 · CA · contact PI
Targeting Cdc42 in leukemia stem cells$298,713
R01 · FY2014 · CA
Targeting the Core Binding Factor tumor suppressor in MLL-fusion AML$224,629
R43 · FY2014 · CA
Genotype and phenotype of chemoresistant AML$161,397
R21 · FY2014 · CA · contact PI
Targeting Cdc42 in leukemia stem cells$289,474
R01 · FY2013 · CA
Genotype and phenotype of chemoresistant AML$199,665
R21 · FY2013 · CA · contact PI
Targeting Cdc42 in leukemia stem cells$307,951
R01 · FY2012 · CA
Targeting Cdc42 in leukemia stem cells$307,531
R01 · FY2011 · CA
The Role of MLL-AF9 in Acute Myeloid Leukemia$370,898
R01 · FY2010 · CA · contact PI
Targeting Cdc42 in leukemia stem cells$315,746
R01 · FY2010 · CA
The Role of CBFb-MYH11 in Acute Myeloid Leukemia$258,529
R01 · FY2010 · CA · contact PI
The Role of CBFb-MYH11 in Acute Myeloid Leukemia$371,211
R01 · FY2009 · CA · contact PI
The Role of MLL-AF9 in Acute Myeloid Leukemia$370,896
R01 · FY2009 · CA · contact PI
The Role of CBFb-MYH11 in Acute Myeloid Leukemia$371,211
R01 · FY2008 · CA · contact PI
The Role of CBFb-MYH11 in Acute Myeloid Leukemia$258,529
R01 · FY2007 · CA · contact PI
RUNX-fusion Target Genes in Normal and Leukemic Hematopoiesis$145,650
R21 · FY2007 · DK · contact PI
The Role of CBFb-MYH11 in Acute Myeloid Leukemia$266,029
R01 · FY2006 · CA · contact PI
RUNX-fusion Target Genes in Normal and Leukemic Hematopoiesis$149,958
R21 · FY2006 · DK · contact PI
Role of AML1/ETO in Hematopoiesis and Leukemogenesis$151,038
K01 · FY2005 · CA
Role of AML1/ETO in Hematopoiesis and Leukemogenesis$151,038
K01 · FY2004 · CA
Role of AML1/ETO in Hematopoiesis and Leukemogenesis$151,038
K01 · FY2003 · CA
Role of AML1/ETO in Hematopoiesis and Leukemogenesis$83,035
K01 · FY2002 · CA
Role of AML1/ETO in Hematopoiesis and Leukemogenesis$46,403
K01 · FY2002 · CA
Role of AML1/ETO in Hematopoiesis and Leukemogenesis$129,438
K01 · FY2001 · CA